The U.S. Department of Energy Isotope Program is pleased to announce cerium-134 (Ce-134) is in routine production and available for purchase. A robust supply of Ce-134 is an essential step in advancing the use of alpha emitters for cancer therapy due to its promise as a PET imaging analog for actinium-225 (Ac-225) and thorium-227 (Th-227).
Lacking imageable photons or positrons, Ac-225 and Th-227 alone do not register on imaging scans, meaning clinicians cannot visualize whether associated drugs are working as intended. When paired with the chemically similar Ce-134 (and its positron-emitting daughter radionuclide, lanthanum-134), in vivo characterization is possible.
Cerium-134 is produced using high-energy proton linear accelerators at the Isotope Production Facility at Los Alamos National Laboratory and the Brookhaven Linac Isotope Producer facility at Brookhaven National Laboratory. Together, these sites enable year-round production of this high impact radionuclide. This is the first global supply chain for Ce-134, enabling emerging technologies and advancing new treatments to combat cancer.
For further inquiries about Ce-134 please contact the NIDC at firstname.lastname@example.org or click the link below to request a quote.